The healthcare system in the United States is in dire need of reform, and the culprit is none other than the 'Big Medicine' conglomerates that have been driving up costs and stifling competition. These entities, including pharmacy benefit managers (PBMs), insurance companies, and drug distributors, have been exploiting their market power to the detriment of both patients and independent providers. The situation is so dire that it warrants a bold solution: breaking up these monopolistic entities.
One of the most concerning aspects of Big Medicine is the way PBMs, such as CVS Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum Rx, control a staggering 80% of U.S. prescriptions. These companies are not only profiting from prescription drugs but also have a vested interest in keeping costs high. For instance, a 2025 report by the Federal Trade Commission revealed that these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors, demonstrating their ability to manipulate drug prices.
The issue extends beyond PBMs. Drug wholesalers like McKesson, Cencora, and Cardinal Health control 96% of U.S. drug distribution and are increasingly vertically integrated with medical providers. This creates conflicts of interest, as seen in the case of Cencora, which agreed to pay $1 million to resolve allegations of paying kickbacks to health care providers. The result is a system where drug prices are dictated by profit margins rather than clinical judgment.
What makes this situation particularly fascinating is the way Big Pharma, with its patent abuses, contributes to the problem. While Big Pharma is blamed for high drug costs, the broader 'Big Medicine' ecosystem, including PBMs, insurance companies, and drug distributors, cannot be absolved of responsibility. The fact that six of the 15 most valuable companies in the U.S. are Big Medicine conglomerates speaks volumes about the concentration of power in the healthcare industry.
The proposed solution, the Break Up Big Medicine Act, is a bold and necessary step towards a more equitable healthcare system. This bipartisan bill would prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers, effectively breaking up the six major Big Medicine companies. Research shows that such a move could reduce drug prices by more than 7%, and public support for this legislation is growing.
What many people don't realize is that the healthcare system's problems are systemic and require structural changes. The Glass-Steagall Act, which separated commercial and investment banks during the Great Depression, provides a precedent for addressing the risks posed by Big Medicine. While breaking up these companies won't heal all the system's problems, it will be a significant step towards recovery. Personally, I think that the concentration of power in the healthcare industry is a critical issue that needs to be addressed, and breaking up Big Medicine is a necessary first step towards a more transparent and patient-centric system.
